A multi-centre, open label, randomised, parallel-group, superiority Trial to compare the efficacy of URsodeoxycholic acid with RIFampicin in the management of women with severe early onset Intrahepatic Cholestasis of pregnancy: the TURRIFIC randomised trial

William M. Hague, Leonie Callaway, Jennifer Chambers, Lucy Chappell, Suzette Coat, Jiska de Haan-Jebbink, Marloes Dekker, Peter Dixon, Jodie Dodd, Maria Fuller, Sanne Gordijn, Dorothy Graham, Oskari Heikinheimo, Annemarie Hennessy, Risto Kaaja, Teck Yee Khong, Laura Lampio, Jennie Louise, Angela Makris, Corey MarkusHanns-Ulrich Marschall, Philippa Middleton, Ben W. Mol, Jonathan Morris, John P. Newnham, Caroline Ovadia, Michael Peek, Antonia Shand, Michael Stark, Jim Thornton, Susanna Timonen, Susan Walker, David Warrilow, Catherine Williamson

Research output: Contribution to journalArticlepeer-review

Abstract

Severe early onset (less than 34 weeks gestation) intrahepatic cholestasis of pregnancy (ICP) affects 0.1% of pregnant women in Australia and is associated with a 3-fold increased risk of stillbirth, fetal hypoxia and compromise, spontaneous preterm birth, as well as increased frequencies of pre-eclampsia and gestational diabetes. ICP is often familial and overlaps with other cholestatic disorders.
Original languageEnglish
Article number51
Number of pages14
JournalBMC Pregnancy and Childbirth
Volume21
Issue number1
Early online date12 Jan 2021
DOIs
Publication statusPublished - 2021

Keywords

  • Intrahepatic cholestasis of pregnancy
  • Cholestatic pruritus
  • Bile acids
  • Ursodeoxycholic acid
  • Rifampicin
  • Maternal and neonatal health outcomes

Fingerprint Dive into the research topics of 'A multi-centre, open label, randomised, parallel-group, superiority Trial to compare the efficacy of URsodeoxycholic acid with RIFampicin in the management of women with severe early onset Intrahepatic Cholestasis of pregnancy: the TURRIFIC randomised trial'. Together they form a unique fingerprint.

Cite this